- Completed
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Updated: Feb 10
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab.
This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in combination with daratumumab or rituximab.
Sponsor
ClinicalTrials.gov Identifier: NCT04136756
Official Title: A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies
First Posted : October 23, 2019
Click here to see details on ClinicalTrials.gov
Drug: NKTR-255
Drug: NKTR-255 Q21
Drug: Rituximab
Drug: Daratumumab
Polymer-conjugated IL-15 Receptor Agonist NKTR-255 (Code C165666)
IL-15 Receptor Agonist NKTR-255
Long-acting Polymer-engineered IL-15 Conjugate NKTR-255
NKTR 255
NKTR-255
NKTR255
Polymer-conjugated IL-15 Receptor Agonist NKTR-255
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies
Future Oncol;. 2021 Sep
Locations
United States, Arizona
United States, California
United States, Florida
United States, Georgia
United States, Illinois
United States, Michigan
United States, Minnesota
United States, New York
United States, North Carolina
United States, Texas
United States, Virginia
United States, Washington